207 related articles for article (PubMed ID: 34991674)
21. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
[TBL] [Abstract][Full Text] [Related]
22. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
Dolloff NG
Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
[TBL] [Abstract][Full Text] [Related]
23. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
24. Bufalin for an innovative therapeutic approach against cancer.
Soumoy L; Ghanem GE; Saussez S; Journe F
Pharmacol Res; 2022 Oct; 184():106442. PubMed ID: 36096424
[TBL] [Abstract][Full Text] [Related]
25. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
26. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
27. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells.
Kim NY; Suh YA; Kim S; Lee C
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32219334
[TBL] [Abstract][Full Text] [Related]
28. Oxidative stress and proteasome inhibitors in multiple myeloma.
Lipchick BC; Fink EE; Nikiforov MA
Pharmacol Res; 2016 Mar; 105():210-5. PubMed ID: 26827824
[TBL] [Abstract][Full Text] [Related]
29. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
30. Novel investigational drugs active as single agents in multiple myeloma.
D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F
Expert Opin Investig Drugs; 2017 Jun; 26(6):699-711. PubMed ID: 28448171
[TBL] [Abstract][Full Text] [Related]
31. Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K/Akt pathway.
Zhu Z; Sun H; Ma G; Wang Z; Li E; Liu Y; Liu Y
Int J Mol Sci; 2012; 13(2):2025-2035. PubMed ID: 22408435
[TBL] [Abstract][Full Text] [Related]
32. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
[TBL] [Abstract][Full Text] [Related]
33. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
34. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Jak-STAT3 pathway enhances bufalin-induced apoptosis in colon cancer SW620 cells.
Zhu Z; Li E; Liu Y; Gao Y; Sun H; Ma G; Wang Z; Liu X; Wang Q; Qu X; Liu Y; Yu Y
World J Surg Oncol; 2012 Oct; 10():228. PubMed ID: 23110625
[TBL] [Abstract][Full Text] [Related]
36. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
[TBL] [Abstract][Full Text] [Related]
37. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
38. Bufalin inhibits the malignant development of non-small cell lung cancer by mediating the circ_0046264/miR-522-3p axis.
Jin J; Yao Z; Qin H; Wang K; Xin X
Biotechnol Lett; 2021 Jun; 43(6):1229-1240. PubMed ID: 33534015
[TBL] [Abstract][Full Text] [Related]
39. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.
Cao F; Gong YB; Kang XH; Lu ZH; Wang Y; Zhao KL; Miao ZH; Liao MJ; Xu ZY
Toxicol Appl Pharmacol; 2019 Sep; 379():114662. PubMed ID: 31301315
[TBL] [Abstract][Full Text] [Related]
40. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma.
Mitra AK; Kumar H; Ramakrishnan V; Chen L; Baughn L; Kumar S; Rajkumar SV; Van Ness BG
Blood Cancer J; 2020 Jul; 10(7):78. PubMed ID: 32724061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
